To the full analysis
Samsung Biologics stock: growth
207940.KSSamsung Biologics reported $3.42B in revenue for fiscal 2025, up 30.3% on the prior year, up 31.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
40.9%
per year from 2014 to 2025, per share 40.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2014 | |
|---|---|---|---|
| Revenue | 31.4% | 47.9% | 40.9% |
| Revenue per share | 29.8% | 46.9% | 40.1% |
| Earnings | 49.2% | −0.7% | no data |
| Earnings per share | 47.4% | −1.3% | no data |
| Free cash flow | 74.1% | no data | no data |
| Free cash flow per share | 72.0% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2014 | $78.82M | −$71.89M | −$513.51M |
| 2015 | $68.42M | $1.44B | −$493.58M |
| 2016 | $220.84M | −$132.54M | −$173.02M |
| 2017 | $348.27M | −$72.69M | −$266.09M |
| 2018 | $401.62M | $167.98M | −$237.52M |
| 2019 | $525.89M | $152.09M | −$128.21M |
| 2020 | $873.08M | $180.63M | $40.12M |
| 2021 | $1.18B | $295.02M | $25.07M |
| 2022 | $2.25B | $598.2M | −$42.11M |
| 2023 | $2.77B | $642.9M | $420.44M |
| 2024 | $2.62B | $812.02M | $211.18M |
| 2025 | $3.42B | $1.34B | $641.68M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₩1,334.10)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 28 Aug 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.